X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs MERCK LTD - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES MERCK LTD PIRAMAL ENTERPRISES/
MERCK LTD
 
P/E (TTM) x 9.1 48.8 18.6% View Chart
P/BV x 3.0 6.4 47.0% View Chart
Dividend Yield % 0.8 0.4 183.0%  

Financials

 PIRAMAL ENTERPRISES   MERCK LTD
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-17
MERCK LTD
Dec-16
PIRAMAL ENTERPRISES/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs2,0951,060 197.6%   
Low Rs1,025623 164.5%   
Sales per share (Unadj.) Rs492.8632.4 77.9%  
Earnings per share (Unadj.) Rs72.645.7 158.7%  
Cash flow per share (Unadj.) Rs94.762.3 151.9%  
Dividends per share (Unadj.) Rs21.0011.00 190.9%  
Dividend yield (eoy) %1.31.3 103.0%  
Book value per share (Unadj.) Rs862.5388.8 221.8%  
Shares outstanding (eoy) m172.5616.60 1,039.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.21.3 237.9%   
Avg P/E ratio x21.518.4 116.8%  
P/CF ratio (eoy) x16.513.5 122.0%  
Price / Book Value ratio x1.82.2 83.6%  
Dividend payout %28.924.1 120.3%   
Avg Mkt Cap Rs m269,19413,969 1,927.1%   
No. of employees `0004.01.6 253.5%   
Total wages/salary Rs m17,9391,487 1,206.6%   
Avg. sales/employee Rs Th21,190.36,631.9 319.5%   
Avg. wages/employee Rs Th4,470.1939.2 476.0%   
Avg. net profit/employee Rs Th3,120.0479.4 650.8%   
INCOME DATA
Net Sales Rs m85,03710,498 810.0%  
Other income Rs m2,338242 964.3%   
Total revenues Rs m87,37410,741 813.5%   
Gross profit Rs m34,9911,135 3,082.1%  
Depreciation Rs m3,817276 1,385.5%   
Interest Rs m20,3100-   
Profit before tax Rs m13,2021,102 1,197.8%   
Minority Interest Rs m1,6990-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-1000-   
Tax Rs m2,281343 664.5%   
Profit after tax Rs m12,520759 1,649.8%  
Gross profit margin %41.110.8 380.5%  
Effective tax rate %17.331.1 55.5%   
Net profit margin %14.77.2 203.7%  
BALANCE SHEET DATA
Current assets Rs m87,5906,410 1,366.6%   
Current liabilities Rs m185,5788,828 2,102.1%   
Net working cap to sales %-115.2-23.0 500.1%  
Current ratio x0.50.7 65.0%  
Inventory Days Days3158 53.8%  
Debtors Days Days4838 123.9%  
Net fixed assets Rs m108,5231,406 7,716.4%   
Share capital Rs m345166 207.9%   
"Free" reserves Rs m148,4816,286 2,362.1%   
Net worth Rs m148,8266,455 2,305.7%   
Long term debt Rs m144,9570-   
Total assets Rs m482,3948,828 5,464.2%  
Interest coverage x1.7NM-  
Debt to equity ratio x1.00-  
Sales to assets ratio x0.21.2 14.8%   
Return on assets %6.88.6 79.2%  
Return on equity %8.411.8 71.6%  
Return on capital %12.017.1 70.0%  
Exports to sales %08.3 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA869 0.0%   
Imports (cif) Rs mNA2,209 0.0%   
Fx inflow Rs m15,001959 1,564.5%   
Fx outflow Rs m5,1502,612 197.2%   
Net fx Rs m9,851-1,653 -595.9%   
CASH FLOW
From Operations Rs m-100,3931,070 -9,379.0%  
From Investments Rs m-24,202-750 3,228.2%  
From Financial Activity Rs m135,705-150 -90,590.5%  
Net Cashflow Rs m11,110171 6,500.7%  

Share Holding

Indian Promoters % 52.9 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 4.0 18.2 22.0%  
FIIs % 26.6 1.0 2,660.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 29.1 56.7%  
Shareholders   93,274 28,591 326.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  ORCHID PHARMA LTD  GSK PHARMA  

Compare PIRAMAL ENTERPRISES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY18); Net Profit Up 1230.7%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 39 bn (up 1230.7% YoY). Sales on the other hand came in at Rs 30 bn (up 21.5% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Jun 22, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES - CIPLA COMPARISON

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS